Cocrystal Pharma, Inc.
COCP · XNASCIK 1412486fmd_1PF1J38015QCS3Q8NTVS1MVS9K制造业 · 医药制剂模板: 标准
覆盖范围: 2010年1月01日 至 2026年6月30日，共 65 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | – | – | – | 7 | 2 | – | – | – | – | – |
| 营业成本 | – | – | – | – | – | – | – | – | – | – |
| 净利息收入 | – | (0) | (0) | (0) | – | – | – | – | – | – |
| 毛利润 | – | – | – | – | – | – | – | – | – | – |
| 研发费用 | 102 | 6 | 5 | 4 | 6 | 9 | 12 | 15 | 13 | 5 |
| 销售、一般及管理费用 | – | – | – | – | – | – | – | – | – | – |
| 营业费用合计 | 106 | 8 | 63 | 55 | 12 | 14 | 39 | 19 | 18 | 9 |
| 营业利润 | (106) | (8) | (63) | (48) | (10) | (14) | (39) | (19) | (18) | (9) |
| 利息费用 | – | – | 0 | 0 | 0 | 0 | 0 | (1) | (1) | (0) |
| 其他营业外收入（支出） | 2 | 1 | 0 | 0 | (0) | 0 | (0) | 1 | 0 | 0 |
| 税前利润 | (104) | (7) | (63) | (48) | (10) | – | – | – | (19) | (9) |
| 所得税费用 | (29) | (7) | (14) | – | – | – | – | – | – | – |
| 持续经营净利润 | (75) | (1) | (49) | – | – | – | – | – | – | – |
| 净利润 | (75) | (1) | (49) | (48) | (10) | (14) | (39) | (18) | (18) | (9) |
| 归属于普通股股东的净利润 | – | (1) | (49) | (48) | – | – | – | – | – | – |